Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Royalty Pharma (RPRX.O) has agreed to acquire a royalty interest in Amgen's (AMGN.O) lung cancer drug, Imdelltra, from BeOne Medicines (688235.SS) for up to $950 million, including an $885 million upfront payment. This strategic acquisition grants Royalty Pharma approximately 7% of the therapy's global net sales, with the royalty duration expected to extend through 2038-2041, significantly expanding its portfolio with a stake in an approved oncology asset, while BeOne retains commercial rights in China.

Analysis

Royalty Pharma (RPRX.O) has executed a significant strategic acquisition, committing up to $950 million to secure a royalty interest in Amgen's (AMGN.O) recently approved lung cancer therapy, Imdelltra. The deal structure, featuring an $885 million upfront payment, provides BeOne Medicines (688235.SS) with substantial immediate capital. For Royalty Pharma, the acquisition of an approximate 7% royalty on global net sales provides a durable, long-term revenue stream expected to extend through 2038-2041. This transaction diversifies RPRX's portfolio with an asset in the high-value oncology space, specifically targeting extensive-stage small cell lung cancer patients who have failed prior chemotherapy. A critical detail for valuation is that BeOne retains commercial rights in China, meaning Royalty Pharma's revenue stream will be derived from global sales excluding this major market. The positive sentiment for RPRX reflects the market's approval of securing a long-duration royalty on an FDA-approved drug, while the neutral sentiment for Amgen is logical, as its payment obligations are unchanged, merely redirected.

Key Decisions for Investors

• Investors in Royalty Pharma should view this as an accretive transaction that enhances long-term revenue visibility and should model the impact of the ~7% royalty stream from Imdelltra's ex-China sales.
• Shareholders of BeOne Medicines should monitor the company's strategic deployment of the $885 million in non-dilutive upfront capital, which could be a significant catalyst for its pipeline development or other corporate actions.
• A key risk factor to monitor is the commercial launch and sales trajectory of Imdelltra, as the ultimate return on Royalty Pharma's investment is directly dependent on the drug's market penetration and adoption.
• For investors in Amgen, this transaction is largely an administrative change and should not materially alter the investment thesis, as its total royalty burden for the drug remains constant.